Migraine Market Overview:
The global migraine market is predicted to grow at a notable CAGR over the forecast period (2013-2022), as per the latest Market Research Future (MRFR) report. Migraine is a common neurological condition which can cause multiple symptoms. Debilitating, intense headaches characterize this condition. Symptoms include sensitivity to sound and light, tingling or numbness, difficulty speaking, vomiting, and nausea. Often migraines run in families and affect every age.
The underlying mechanism of migraine is not fully known. However, increasing incidences of migraine that is triggered due to other causative disorders are fueling the growth of the global migraine market. Absence of permanent cure for migraine and growing genericization of drugs are creating multiple opportunities for pharmaceutical companies to introduce effective medication and treatment for the condition, leading to the growth of the global migraine market size.
Migraine is common in women compared to men, chiefly on account of the fluctuations that take place in the hormones. It is characterized into two types, migraine without aura or common migraines and migraine with aura called classical migraines. Usually, aura includes visual symptoms such as seeing flashes, shapes, or seeing lines. Often people may lose their vision for some time. Besides, they may also feel a tingling sensation in their legs and arms. The severity and symptoms can differ by attack, person, and over time.
Migraine Market Segmentation:
The Market Research Future report provides a wide segmental analysis of the migraine market based on drug class, treatment types, and types.
- Based on type, the migraine market is segmented into chronic and episodic.
- Based on drugs, the migraine market is segmented into ergots,triptans, and others.
- Based on treatment types, the migraine market is segmented into abortive and preventive.
Migraine Market Regional Analysis:
Based on the region, the migraine market report covers the latest trends and growth opportunities across Europe, Asia Pacific (APAC), North America, and the Rest of the World (RoW). Of these, North America will spearhead the market over the forecast period. The US is the key contributor in this region with more than 37 million suffering from migraine in the US alone. Besides, the other factors contributing to the market growth in this region include the huge target population in the US, adoption of new therapeutics, and the launch of CGRP based therapies.
The migraine market in the Asia Pacific is likely to have a healthy growth over the forecast period. This is owing to a huge underserved population, growing disease awareness, low-cost production of drugs, and rising healthcare expenditure.
The migraine market in Europe is predicted to have significant growth in the market over the forecast period. This is on account of the rising prevalence of hormonal imbalance, changing lifestyles, and rising stress levels.
Migraine Market Players:
Leading players profiled in the migraine market report include GlaxoSmithKline plc, AstraZeneca plc, OptiNose, Merck, Meda, Luitpold Pharmaceuticals, Kowa Pharmaceuticals America, Klaria, Johnson Johnson, Pfizer, Inc., Eli Lilly and Company, Eisai Inc., Abbott Laboratories, Inc., Impax Laboratories, and Allergan, among others. Key players have acquired several strategies to strengthen their position and create a foothold in the market. These include partnerships, acquisitions, mergers, product innovation, and product launch, expansion, research, and development activities, among others.
August 2019: DW Healthcare Partners recently has acquired CEFALY Technology SPRL, the leading Belgian manufacturers of neuro-modulating medical devices used to prevent and treat migraines. The CEFALY device is applied externally on the forehead of the patient. It delivers electrical impulses to a vital component of the nervous system, the trigeminal nerve that is involved in almost every migraine. This is a one of a kind device that is CE mark certified, registered with the FDA, and with several years of active commercial usage. The company’s robust and strong clinical data has successfully established CEFALY as an immensely effective as well as a safe solution for preventing and alleviating acute migraine pain.
Among others are some key companies in the global Migraine that are listed by MRFR for market research.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071